Your fact-checks will appear here
UK health agency
Early data and surveillance through mid‑2025–2026 show the current seasonal flu vaccines still cut the risk of severe illness and hospitalization — roughly 70–75% protection for children and about 30–...
Early real-world studies from the United Kingdom and pooled European surveillance indicate that the 2025–26 seasonal influenza vaccine retains meaningful protection against the emergent H3N2 subclade ...
Available reporting does not provide a single, clear national figure for “how many people in hospital with the flu had the flu vaccine” in the UK; instead, early UKHSA and media analyses report vaccin...
The 2025–26 UK flu vaccine was formulated to include influenza A H1N1, influenza A H3N2 and an influenza B component; UKHSA and other coverage say the H1N1 component is well matched, while a drifted H...
Available sources show this season’s vaccine is estimated to reduce hospital attendance or admission by roughly 70–75% in children and 30–40% in adults, and public reporting indicates substantial hosp...
This season’s early UK data show the 2025/26 vaccine is providing strong protection in children (estimated 70–75% effective at preventing hospital attendance for ages 2–17) and more modest protection ...
Early 2025–26 data show the Northern Hemisphere vaccine still protects against current H3N2 activity: UK analyses estimate 70–75% effectiveness at preventing hospital attendance in children (2–17 year...
Available reporting shows a new H3N2 “subclade K” with roughly seven additional mutations emerged in 2025 and is widespread; laboratory and sequence data indicate those mutations reduce recognition by...
Europe is seeing early, rising influenza activity dominated by A(H3N2) “subclade K” (formerly J.2.4.1), which accounted for about one-third of global A/H3N2 sequences May–Nov 2025 and “almost half” of...
Reino Unido enfrenta un brote intenso de la variante H3N2 subclado K que ha adelantado la temporada gripal y forzado cierres temporales de colegios; informes citan aumentos de ingresos hospitalarios d...
Large-scale reviews and public-health agencies report that masks reduce respiratory-virus transmission, with meta-analyses finding modest reductions (about 6–15%) and some randomized and community tri...
The UK has shifted its national programme from quadrivalent to trivalent influenza vaccines because WHO and EU/UK advisers judge B/Yamagata absent since March 2020; all vaccines marketed for 2025–26 i...
The UK’s 2024–25 seasonal flu vaccination programme reduced the risk of hospital attendance and admission, with stronger protection in children than adults: early UKHSA analyses and media summaries re...
Early test‑negative real‑world studies from England report that the 2025–26 seasonal vaccine is reducing medically attended H3N2 (subclade K–dominated) illness by roughly 70–75% in children and about ...
Early real-world data from the UK indicate the 2025–26 vaccine is reducing hospital attendance for pediatric H3N2 cases by about 70–75% and by roughly 30–40% in adults, even as a drifted H3N2 “subclad...
The H3N2 “subclade K” virus is a genetic offshoot of the influenza A H3N2 family and differs enough from the strain chosen for this season’s vaccine that lab tests show reduced antibody recognition, b...
Early real-world data from the UK show the 2025–26 vaccine is reducing hospital attendance for children aged 2–17 by roughly 70–75% and protecting adults at substantially lower levels—about 30–40% aga...
Available sources do not give a single national percentage for "what percentage of hospitalized flu patients in the UK were vaccinated in the 2024–2025 season"; detailed vaccine‑status breakdowns for ...
Real‑world UK data show the 2025–26 seasonal vaccine—designed with different H3N2 strains for egg‑based and for cell/recombinant products—still provided substantial protection against severe outcomes ...
WHO’s advisory group recommended A/Croatia/10136RV/2023-like as the A(H3N2) component for Northern Hemisphere 2025–26 trivalent (egg-based) vaccines; WHO also selected different H3N2 candidates for So...